Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 49 for “"Biosimilars"”.

  1. Evaluating biosimilars uptake and policy in Canada

    … to generics for small molecule drugs, biologic biosimilars are one potential way in which payers can reduce drug spending. In 2019, the government of British Columbia became the first in North America to mandate switching from reference biologics to biosimilars. While a number of other provinces …

    ubc Repository record for Evaluating biosimilars uptake and policy in Canada (opens in a new tab) Download PDF for Evaluating biosimilars uptake and policy in Canada (opens in a new tab)

  2. Η διαδικασία ανάπτυξης biosimilars - προκλήσεις και ερωτήματα

    Στη σύγχρονη εποχή των επιστημονικών επιτευγμάτων τα βιο-ομοειδή φάρμακα αποτελούν ένα από τα κυριότερα βιοτεχνολογικά εργαλεία με στόχο την αντιμετώπιση χρόνιων ασθενειών. Με τη βοήθεια τους είναι πλέον εφικτή η διαχείριση σοβαρών παθήσεων όπως οι νεοπλασίες, παρέχοντας στους ασθενείς πρόσβαση σε …

    athens Repository record for Η διαδικασία ανάπτυξης biosimilars - προκλήσεις και ερωτήματα (opens in a new tab)

  3. Evaluating the Impact of Biosimilars in the Drug Market

    … U.S lawmakers have changed legislation so that biosimilars can be added into the drug market in hopes of creating affordable products. Biosimilars allow more options for consumers and add increased competition for manufactures which should decrease the overall price of the original …

    rit Repository record for Evaluating the Impact of Biosimilars in the Drug Market (opens in a new tab)

  4. Statistical considerations of noninferiority, bioequivalence and equivalence testing in biosimilars studies

    … development of follow-on biological products (biosimilars) has received increasing attention. The dissertation covers statistical methods related to three topics of Non-inferiority (NI), Bioequivalence (BE) and Equivalence in demonstrating biosimilarity. For NI, one of the key requirements is …

    bu Repository record for Statistical considerations of noninferiority, bioequivalence and equivalence testing in biosimilars studies (opens in a new tab)

  5. Biosimilars: A New Look on Process Innovation and the Impact of Competitive Dynamics

    … in attempt to lower the costs of biologics. Biosimilars may be viewed as a “pure” or distinct type of process innovation completely separate from product innovation due to the Regulatory requirements and this novel phenomenon allows, perhaps for the first time, process innovation to be …

    temple Repository record for Biosimilars: A New Look on Process Innovation and the Impact of Competitive Dynamics (opens in a new tab)

  6. Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs

    BackgroundThe United States biosimilars market is growing rapidly and has led to significant savings for the health care system and payers. However, market complexities, barriers to entry, and fewer biosimilars in the pipeline than expected has led to concerns about the long-term sustainability of …

    washington Repository record for Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs (opens in a new tab)

  7. Improving the Transition to Biosimilars: The Influence of Communication Strategies, Companions and Patient Concerns

    … from original biologics (bio-originators) to biosimilars to reduce cost and improve access, patient resistance and hesitancy have dampened their uptake. To date, it is unclear how to communicate the transition to ensure patients accept biosimilars. Patients are also frequently accompanied to …

    auckland-ms Repository record for Improving the Transition to Biosimilars: The Influence of Communication Strategies, Companions and Patient Concerns (opens in a new tab)

  8. Optimizing The Clinical Efficacy And Safety Of Biological Medicines And Their Biosimilars Within Available Resources In Europe

    … produced or extracted from a biological source. Biosimilars offer significant opportunities to reduce the price of biological medicines especially in an area of spiralling healthcare expenditure. Given the complexity of these medicines, their role in the management of many diseases, and their …

    the-open-u Download PDF for Optimizing The Clinical Efficacy And Safety Of Biological Medicines And Their Biosimilars Within Available Resources In Europe (opens in a new tab)

  9. Revisión del uso de los medicamentos biosimilares vs. biológicos: implicaciones para la salud en Colombia.

    … describe the health implications with the use of biosimilars compared with biological drugs in Colombia. Also, described the regulatory context about the use of biosimilars, recommendations and guidelines on safety and effectiveness of using biosimilar and biological medicines, based on their …

    rosario Repository record for Revisión del uso de los medicamentos biosimilares vs. biológicos: implicaciones para la salud en Colombia. (opens in a new tab)

  10. Comparative Effect of Herceptin and Its Biosimilar: Transcriptomic and Proteomic Insights from HER2-Positive Cancer Cell Lines

    … in 2019, opening the door for the development of biosimilars. Biosimilars are copies of the originator product that must demonstrate biosimilarity for regulatory approval. This is a very difficult task. Antibodies are large molecules that undergo extensive post-translational modifications (PTMs), …

    waterloo Repository record for Comparative Effect of Herceptin and Its Biosimilar: Transcriptomic and Proteomic Insights from HER2-Positive Cancer Cell Lines (opens in a new tab)

  11. Verbrauch von originären und biosimilaren Erythropoetinen bei Patienten mit renaler Anämie -

    … ESAs (Erstanbieterpräparate vs. Biosimilars, kurzwirksames vs. langwirksames Erythropoetin) in verschiedenen Nutzerkohorten chronisch nierenkranker Patienten mit renaler Anämie und eine Abschätzung ihrer Äquivalenz (Vergleich auf Äquivalenz). (2) die Berechnung …

    lmu-germany Repository record for Verbrauch von originären und biosimilaren Erythropoetinen bei Patienten mit renaler Anämie - (opens in a new tab)

  12. A requirement analysis of software tools for biosimilar development process : enhancing the functionality of Alvotech’s development blueprint

    … has grown correspondingly. The development of biosimilars needs efficient planning and scheduling for their success. Alvotech, a biopharmaceutical company that specializes in creating biosimilars, utilizes a structured process framework for their development process called the ‘Alvotech …

    reykjavik Repository record for A requirement analysis of software tools for biosimilar development process : enhancing the functionality of Alvotech’s development blueprint (opens in a new tab)

  13. Análisis de perdurabilidad de las Instituciones Prestadoras de Salud (IPS), especializadas en tratamiento de enfermedades de alto costo en el departamento de Antioquia, frente a las políticas de regulación de precios por medio de la Ley 1438 en Colombia

    … policy of medicine price regulation and theirs biosimilars entering the country. This research analyzes the sustainability in the Institutions Health Institutions ( IPS ) specialized in treating diseases of high cost , such as: Medicarte , Clinic Astorga, Clinic Life, Helpharma , Audifarma , and …

    rosario Repository record for Análisis de perdurabilidad de las Instituciones Prestadoras de Salud (IPS), especializadas en tratamiento de enfermedades de alto costo en el departamento de Antioquia, frente a las políticas de regulación de precios por medio de la Ley 1438 en Colombia (opens in a new tab)

  14. Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies

    … countries have established approval pathways for biosimilars with the aim of reducing the price of biologics through increased market competition. Once a biosimilar is approved by the FDA, individual states can influence the uptake of the products through legislation at the state level. In …

    washington Repository record for Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies (opens in a new tab)

  15. Statistical Analysis for Differential Hydrogen Exchange-Mass Spectrometry Measurements

    … of protein therapeutics and HOS similarity of biosimilars. However, a question frequently asked is “When is a difference in HX significant and meaningful?”. The widespread use of HX-MS has emphasized addressing this question. In particular, HOS comparability studies of protein therapeutics and …

    ku Repository record for Statistical Analysis for Differential Hydrogen Exchange-Mass Spectrometry Measurements (opens in a new tab)

  16. Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

    Importance. Targeted policy efforts regarding biosimilars need to be informed by empirical evidence as to their cost containment potential. The 2015 launch of filgrastim-sndz, the first U.S. biosimilar, provides a natural experiment in which to evaluate the biosimilar experience in the United …

    jhu Repository record for Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products (opens in a new tab)

  17. Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis

    … in the TNFi classification, and authorized 19 biosimilars for five bDMARDs. After standardization, the trend revealed a significant increase in the costs of TNFi bDMARDs and a substantial decrease following FDA authorization of biosimilars for infliximab, rituximab, and adalimumab. The annual …

    chapman Repository record for Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis (opens in a new tab)

  18. Product scheduling a two-stage distributed hybrid flow shop

    Biosimilar companies produce biosimilars to provide enhanced quality of life. When a new biosimilar is launched on the market, adjustments need to be made in the production plan and to the production processes to ensure the machines can handle the increased production and demand. This project uses …

    reykjavik Repository record for Product scheduling a two-stage distributed hybrid flow shop (opens in a new tab)

Page 1 of 3